Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 6/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.81 |
| ▸ | FLT3 | P36888 | 5/20 | 0.71 |
| ▸ | KDR | P35968 | 5/20 | 0.71 |
| ▸ | KIT | P10721 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.65 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.65 |
| ▸ | TUBB | P07437 | 1/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.65 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.65 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.65 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728118 | 1.00 | TLK2 (1.00) | TLK2PDPK1FLT3KDRKIT | |
| SCHEMBL5728024 | 0.90 | TLK2 (1.00) | TLK2PDPK1FLT3KDRFLT4 | |
| SCHEMBL5728025 | 0.90 | TLK2 (1.00) | TLK2PDPK1FLT3KDRFLT4 | |
| SCHEMBL5728676 | 0.83 | TLK2 (1.00) | TLK2PDPK1FLT3KDRFLT4 | |
| SCHEMBL5728679 | 0.83 | TLK2 (1.00) | TLK2PDPK1FLT3KDRFLT4 | |
| SCHEMBL15328030 | 0.82 | FLT3 (1.00) | TLK2FLT3KDRKITFLT4 | |
| SCHEMBL18060032 | 0.82 | FLT3 (1.00) | TLK2FLT3KDRKITFLT4 | |
| SCHEMBL6966133 | 0.80 | PDPK1 (0.77) | TLK2PDPK1FLT3KDRKIT | |
| SCHEMBL6955194 | 0.80 | PDPK1 (0.77) | TLK2PDPK1FLT3KDRKIT | |
| SCHEMBL5728403 | 0.80 | PDGFRB (0.80) | TLK2PDPK1FLT3KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | TLK2 847/4885PDPK1 4/4885FLT3 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.